Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Interim Results from the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib in Pulmonary Arterial Hypertension

Thursday, August 15, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses interim results from the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib, a treatment for Pulmonary Arterial Hypertension (PAH). The study aims to evaluate the efficacy and safety of Seralutinib in patients. Positive interim results indicate potential benefits for patients suffering from this condition.
Price reaction · baseline $0.827 (2024-08-14 close) · hit pre-market · 2 other GOSS headline(s) in the window, move may be shared
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Interim results show potential benefits of Seralutinib.
  • Study focuses on Pulmonary Arterial Hypertension, a significant health issue.
  • The TORREY study includes both Phase 1B and Phase 2 data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Interim Results from the Phase 1B and Phase 2 TORREY Open-Label Extension Study of Seralutinib in Pulmonary Arterial Hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the TORREY study?

The TORREY study is an open-label extension study evaluating Seralutinib in PAH.

What phases are included in the TORREY study?

The study includes both Phase 1B and Phase 2 evaluations.

What condition does Seralutinib target?

Seralutinib is being studied for its effects on Pulmonary Arterial Hypertension.

What were the results of the interim analysis?

The interim results indicate potential benefits of Seralutinib for patients.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib Pulmonary Arterial Hypertension TORREY study Phase 1B Phase 2
Last updated: Aug 15, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →